SPARQL | HTML5 RDFa and Microdata document
  • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Interaction/d37cb
    • http://vocabularies.wikipathways.org/gpml#hasComment
      • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Comment/d7f3aac3dbfd8d4144d5d9007d54ae40
  • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Comment/d7f3aac3dbfd8d4144d5d9007d54ae40
    • http://www.w3.org/1999/02/22-rdf-syntax-ns#type
      • http://vocabularies.wikipathways.org/gpml#Comment
    • http://purl.org/dc/terms/isPartOf
      • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Interaction/d37cb
    • http://vocabularies.wikipathways.org/gpml#commentText
      • 9439849 (Organ: hypothalamic, Tissue: cortex) These results suggest that fluoxetine gradually increases the G-protein coupling of 5-HT2A/2C receptors without altering the levels of Gq- or G11-proteins. 12721328 (Organ: hypothalamic, Tissue: cortex, CellType: neural) These fluoxetine-induced changes in 5-HT2A receptor signaling occur without changing the levels of Galphaq or RGS4 proteins.